Ortho Regenerative reaches big milestone in phase I/II rotator cuff tear repair clinical trial

Ortho Regenerative Technologies CEO Philippe Deschamps says the company has reached the most significant milestone to date with the enrollment of its first patient in the US Phase I/II rotator cuff tear repair clinical trial.

The second patient in the trial has already been scheduled, with more to follow as it targets the end of September for the Phase 1 safety portion of the clinical program.

“What we’re doing now is working with potential development partners to look at who might help us after phase 2 to continue to develop this asset in both rotator cuff and other indications,” Deschamps said.

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews